下肢淋巴水肿居家先进气压压缩治疗的健康相关生活质量与临床结局纵向评估
这项前瞻性纵向实用性研究在四个退伍军人事务中心纳入下肢淋巴水肿患者,评估居家使用专有先进气压压缩装置的效果。主要结局为淋巴水肿生活质量问卷和SF-36v2,次要结局为肢体周径、蜂窝织炎事件、皮肤质量和依从性。结果显示治疗12周及随访至52周时,疾病特异性生活质量各领域及总体评分均显著改善,肢体周径减小、蜂窝织炎新发事件减少、皮肤色素沉着减轻,依从性良好。
要点
- 居家先进气压压缩治疗12周后淋巴水肿生活质量各领域及总体评分显著改善,并持续至52周。
- 52周时平均肢体周径较基线减少1.4 cm(P < .0001),ISL II和III期肢体12周时最大减少1.9 cm(6.0%)。
- 有既往蜂窝织炎史患者的新发蜂窝织炎事件从21.4%降至6.1%(P = .001),皮肤色素沉着从75%降至40%(P < .01)。
核心结论
- 退伍军人事务中心下肢淋巴水肿患者居家使用先进气压压缩装置,至52周时通用和疾病特异性健康相关生活质量均改善,肢体周径、蜂窝织炎事件和皮肤变色减少,依从性良好。
研究设计与样本
- 前瞻性纵向实用性研究,经机构审查委员会批准,四个退伍军人事务中心于2016年至2022年纳入下肢淋巴水肿患者。
- 179例患者完成52周随访,143例在所有时间点均有完整测量。
- 主要结局为基线和12、24、52周的健康相关生活质量问卷(淋巴水肿生活质量-腿和通用SF-36v2)。
- 次要结局为肢体周径、蜂窝织炎事件、皮肤质量以及对先进气压压缩装置和其他压缩治疗的依从性。
主要发现
- 基线平均年龄66.9 ± 10.8岁,91%为男性,平均体重指数33.8 ± 6.9 kg/m2,92.2%为双侧下肢淋巴水肿。
- 慢性静脉功能不全或静脉淋巴水肿为最常见病因(112例;62.6%),其次为创伤或手术(20例;11.2%),癌症治疗作为病因较低(4例;2.3%)。
- 国际淋巴学会分期I期68.4%、II期27.6%、III期4.1%。
- 淋巴水肿生活质量-腿的功能、外观、症状、情绪各领域及总体评分在治疗12周后显著改善(P < .0001),并持续至52周随访。
- SF-36v2在12周时三个领域显著改善,52周时躯体功能、躯体疼痛、躯体成分(P < .0001)、社会功能(P = .0181)、角色-躯体(P < .0005)和心理健康(P < .0334)六个领域显著改善。
关键数值与推荐
- SF-36v2评分<40表明下肢淋巴水肿患者健康相关生活质量较美国常模大幅降低。
- 依从性定义为每周使用5至7天,52周时先进气压压缩装置为72%,弹力袜为74%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 由于部分试验在2019年冠状病毒病大流行期间进行,179例患者有52周随访,143例在所有时间点有完整测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This prospective, longitudinal, pragmatic study describes at home treatment with a proprietary advanced pneumatic compression device (APCD) for patients with lower extremity lymphedema (LED). METHODS: Following institutiona review board approval, four participating Veterans Affairs centers enrolled LED patients from 2016 to 2022. The primary outcome measures were health-related quality of life (HR-QoL) questionnaires (lymphedema quality of life-leg and the generic SF-36v2) obtained at baseline and 12, 24, and 52 weeks. The secondary outcome measures were limb circumference, cellulitis events, skin quality, and compliance with APCD and other compression therapies. RESULTS: Because a portion of the trial was conducted during the coronavirus disease 2019 pandemic, 179 patients had 52 weeks of follow-up, and 143 had complete measurements at all time points. The baseline characteristics were a mean age of 66.9 ± 10.8 years, 91% were men, and the mean body mass index was 33.8 ± 6.9 kg/m2. LED was bilateral in 92.2% of the patients. Chronic venous insufficiency or phlebolymphedema was the most common etiology of LED (112 patients; 62.6%), followed by trauma or surgery (20 patients; 11.2%). Cancer treatment as a cause was low (4 patients; 2.3%). Patients were classified as having International Society for Lymphology (ISL) stage I (68.4%), II (27.6%), or III (4.1%). Of the primary outcome measures, significant improvements were observed in all lymphedema quality of life-leg domains of function, appearance, symptoms, and emotion and the overall score after 12 weeks of treatment (P < .0001) and through 52 weeks of follow-up. The SF-36v2 demonstrated significant improvement in three domains at 12 weeks and in the six domains of physical function, bodily pain, physical component (P < .0001), social functioning (P = .0181), role-physical (P < .0005), and mental health (P < .0334) at 52 weeks. An SF-36v2 score <40 indicates a substantial reduction in HR-QoL in LED patients compared with U.S. norms. Regarding the secondary outcome measures at 52 weeks, compared with baseline, the mean limb girth decreased by 1.4 cm (P < .0001). The maximal reduction in mean limb girth was 1.9 cm (6.0%) at 12 weeks in ISL stage II and III limbs. New episodes of cellulitis in patients with previous episodes (21.4% vs 6.1%, P = .001) were reduced. The 75% of patients with skin hyperpigmentation at baseline decreased to 40% (P < .01) at 52 weeks. At 52 weeks, compliance, defined as use for 5 to 7 days per week, was reported for the APCD by 72% and for elastic stockings by 74%. CONCLUSIONS: This longitudinal study of Veterans Affairs patients with LED demonstrated improved generic and disease-specific HR-QoL through 52 weeks with at home use of an APCD. Limb girth, cellulitis episodes, and skin discoloration were reduced, with excellent compliance.
引用
- Padberg FT, Ucuzian A, Dosluoglu H, et al. Longitudinal assessment of health-related quality of life and clinical outcomes with at home advanced pneumatic compression treatment of lower extremity lymphedema. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38636734. doi:10.1016/j.jvsv.2024.101892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。